1. Home
  2. REKR vs CGEN Comparison

REKR vs CGEN Comparison

Compare REKR & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rekor Systems Inc.

REKR

Rekor Systems Inc.

HOLD

Current Price

$1.35

Market Cap

216.5M

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$2.09

Market Cap

220.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REKR
CGEN
Founded
2017
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
216.5M
220.7M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
REKR
CGEN
Price
$1.35
$2.09
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
2.5M
591.9K
Earning Date
11-13-2025
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$49,028,000.00
$6,903,000.00
Revenue This Year
$11.82
N/A
Revenue Next Year
$22.78
$164.92
P/E Ratio
N/A
N/A
Revenue Growth
11.89
N/A
52 Week Low
$0.62
$1.13
52 Week High
$3.42
$2.66

Technical Indicators

Market Signals
Indicator
REKR
CGEN
Relative Strength Index (RSI) 33.55 59.54
Support Level $1.33 $2.04
Resistance Level $1.79 $2.21
Average True Range (ATR) 0.08 0.15
MACD -0.01 0.02
Stochastic Oscillator 4.37 60.18

Price Performance

Historical Comparison
REKR
CGEN

About REKR Rekor Systems Inc.

Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which a majority of its revenue comes from the United States.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: